Xuan Lei Selected Research

morpholinoanthracycline MX2 (MX-2)

5/2016

Improving the N-terminal diversity of sansanmycin through mutasynthesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xuan Lei Research Topics

Disease

3	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 01/2021
3	Neoplasms (Cancer) 01/2022 - 01/2013
3	Infections 02/2021 - 01/2017
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Osteoarthritis 07/2021
1	Sepsis (Septicemia) 01/2021
1	Acute Lung Injury 01/2021
1	Osteonecrosis (Kienbock's Disease) 10/2020
1	Bacterial Infections (Bacterial Infection) 01/2017
1	Tuberculosis (Tuberculoses) 05/2016

Drug/Important Bio-Agent (IBA)

2	norvancomycinIBA 02/2021 - 01/2017
1	Long Noncoding RNAIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2022
1	Serotonin (5 Hydroxytryptamine)IBA 01/2021
1	5-Hydroxytryptophan (5 Hydroxytryptophan)IBA 01/2021
1	chuangxinmycinIBA 03/2018
1	morpholinoanthracycline MX2 (MX-2)IBA 05/2016
1	sansanmycinIBA 05/2016
1	Pharmaceutical PreparationsIBA 05/2016
1	IsotopesIBA 01/2013

Therapy/Procedure

2	Immunotherapy 01/2022 - 01/2021
1	Immunomodulation 01/2022
1	Injections 07/2021
1	Ligation 01/2021
1	Punctures 01/2021
1	Therapeutics 10/2020